Evaluation of the Efficacy and Safety of DMR Using the Revita® in Subjects With Inadequately Controlled Type 2 Diabetes
A trial with no phase registered on ClinicalTrials.gov. The registry status is suspended. It plans to enroll 320 participants.
Also called NCT04419779
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 320 participants
- Sponsor
- Fractyl Health Inc.
- Registry
-
NCT04419779
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Belgium, Ireland, Italy, Netherlands, Switzerland, United Kingdom
- Registry status
- Suspended
Technical summary
Registry record NCT04419779. Randomized; quadruple masking; primary purpose treatment. Start 2021-03-08 (actual); primary completion 2026-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluation of the Efficacy and Safety of DMR Using the Revita® in Subjects With Inadequately Controlled Type 2 Diabetes
- Acronym
- REVITALIZE 1
- Condition
- Type 2 Diabetes
- Intervention (Device)
- Duodenal Mucosal Resurfacing (DMR)
- Intervention (Device)
- Duodenal Mucosal Resurfacing (Sham)
- Lead sponsor
- Fractyl Health Inc.
Record details
- Record id
cardio:ct-nct04419779- Content hash
932d80360eb90c3e58788d7702dc16caf85e95a3bbe57d5ff5bac42035b21770